Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
56.06
-0.97 (-1.70%)
Nov 22, 2024, 4:00 PM EST - Market closed
Crinetics Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 1.04 | 4.01 | 4.74 | 1.08 | 0.07 | 1.19 | Upgrade
|
| Revenue Growth (YoY) | -78.00% | -15.28% | 339.42% | 1418.31% | -94.05% | -50.86% | Upgrade
|
| Cost of Revenue | 50.64 | - | - | - | 57 | 41.51 | Upgrade
|
| Gross Profit | -49.6 | 4.01 | 4.74 | 1.08 | -56.93 | -40.31 | Upgrade
|
| Selling, General & Admin | 88.64 | 58.09 | 42.39 | 24.53 | 18.03 | 13.52 | Upgrade
|
| Research & Development | 168.53 | 168.53 | 130.23 | 84.26 | - | - | Upgrade
|
| Operating Expenses | 257.16 | 226.62 | 172.62 | 108.78 | 18.03 | 13.52 | Upgrade
|
| Operating Income | -306.77 | -222.61 | -167.88 | -107.7 | -74.95 | -53.83 | Upgrade
|
| Interest & Investment Income | 33.79 | 13.44 | 4.32 | 0.16 | 0.99 | 3.46 | Upgrade
|
| Earnings From Equity Investments | -4.67 | -5.2 | -1.01 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.02 | 0.03 | -0.11 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.22 | -0.14 | 0.63 | 0.01 | 0.15 | -0.05 | Upgrade
|
| Pretax Income | -277.91 | -214.53 | -163.92 | -107.64 | -73.81 | -50.42 | Upgrade
|
| Net Income | -277.91 | -214.53 | -163.92 | -107.64 | -73.81 | -50.42 | Upgrade
|
| Net Income to Common | -277.91 | -214.53 | -163.92 | -107.64 | -73.81 | -50.42 | Upgrade
|
| Shares Outstanding (Basic) | 75 | 58 | 52 | 38 | 30 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 75 | 58 | 52 | 38 | 30 | 24 | Upgrade
|
| Shares Change (YoY) | 36.52% | 11.71% | 35.24% | 26.23% | 25.95% | 99.10% | Upgrade
|
| EPS (Basic) | -3.72 | -3.69 | -3.15 | -2.80 | -2.42 | -2.09 | Upgrade
|
| EPS (Diluted) | -3.72 | -3.69 | -3.15 | -2.80 | -2.42 | -2.09 | Upgrade
|
| Free Cash Flow | -203.56 | -171 | -116.86 | -89.02 | -62.21 | -46.87 | Upgrade
|
| Free Cash Flow Per Share | -2.73 | -2.94 | -2.25 | -2.32 | -2.04 | -1.94 | Upgrade
|
| Gross Margin | - | 100.00% | 100.00% | 100.00% | - | - | Upgrade
|
| Operating Margin | -29525.22% | -5547.17% | -3544.06% | -9990.91% | -105567.61% | -4512.32% | Upgrade
|
| Profit Margin | -26747.83% | -5345.85% | -3460.38% | -9985.25% | -103960.56% | -4226.49% | Upgrade
|
| Free Cash Flow Margin | -19592.01% | -4261.03% | -2466.98% | -8258.26% | -87623.94% | -3929.00% | Upgrade
|
| EBITDA | -304.51 | -221.51 | -166.9 | -106.78 | -74.01 | -52.95 | Upgrade
|
| D&A For EBITDA | 2.26 | 1.1 | 0.98 | 0.92 | 0.95 | 0.89 | Upgrade
|
| EBIT | -306.77 | -222.61 | -167.88 | -107.7 | -74.95 | -53.83 | Upgrade
|
| Revenue as Reported | - | - | - | - | 0.07 | 1.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.